BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. - Test2 - elhamkhani - TriplyDB

BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.

BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.

http://www.wikidata.org/entity/Q38039906

about

Molecular Assays in Cytopathology for Thyroid Cancer Progress in molecular-based management of differentiated thyroid cancer BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules.The Role of Central Neck Lymph Node Dissection in the Management of Papillary Thyroid Cancer BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma.The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients Diagnostic value of BRAF (V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis.Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.Practice patterns among thyroid cancer surgeons: implications of performing a prophylactic central neck dissection.Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules Update on the molecular diagnosis and targeted therapy of thyroid cancer.Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer.Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy.Nodal metastases in thyroid cancer: prognostic implications and management.CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma.Hashimoto's Thyroiditis Does Not Affect Ultrasonographical, Cytological, and Histopathological Features in Patients with Papillary Thyroid Carcinoma.Patterns and clinical significance of cervical lymph node metastasis in papillary thyroid cancer patients with Delphian lymph node metastasis.BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma.The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.Application of metabolomics in prediction of lymph node metastasis in papillary thyroid carcinoma.Metadherin Expression is Associated with Extrathyroidal Extension in Papillary Thyroid Cancer Patients.The Prediction of Sonographic features and BRAF Mutation for Central Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: Reply.The Significance of BRAF V600e Mutation and Preoperative Ultrasound for Central Compartment Lymph Node Metastasis in Papillary Thyroid Microcarcinoma.

P2860

Q26823658-874499E8-DCA2-4A1D-B5D2-C947E0CF99CB Q26999887-5C38B867-D28C-4E01-849E-33716E0D4F6D Q28075975-EC0F0583-36DA-47A8-855E-AB7C6CBD12BD Q30367068-7175684C-EC39-4112-BC11-19390507EC35 Q33782114-F7116DBB-FBF4-4C68-AC4E-EE026BF48E7F Q33810411-CA5139B8-9C88-4B64-AF81-FFD218713996 Q33875906-F7BDA40F-C56A-4440-9EED-C884C14FA0E7 Q33909962-4DAB2F22-9A2F-4139-A58B-F739E5DC8F3F Q33973108-8265B399-9148-4401-A4A8-A97BE870A518 Q33973118-1071BD61-AED9-4083-8E11-E5C3F783EC35 Q34388349-C7609F71-FD55-479A-B761-5DC4CFB30AC3 Q34520869-6516CE99-A738-4394-94D8-0E15F1306FAA Q35098287-15B45CD3-A950-4FCC-8E2C-DDA29E1D4D25 Q35145064-83B8A505-71E4-419F-92EF-D86060A67C9E Q35345217-4D564607-093A-4BF8-B868-57345571A672 Q35692478-6CB02852-1D2A-4659-B399-FA8FCB79E2C2 Q35755353-DB676BA2-F7DE-48FB-83EE-6D9EB7E52CA9 Q35932262-2EE6BC50-E05E-4FB2-BB36-E1393AAA1AFC Q36016602-1EFE81F3-87F9-48CE-867E-DDB0153EEBB1 Q36339926-A07C96CC-B5B6-425D-B594-1E457E117D01 Q36468764-61A06C6F-A352-443E-8C5F-D425D1B6E45E Q36786213-DAFD37A2-93E9-4009-ACC9-3AC2EBA04026 Q37188539-589E191B-52DA-4E5A-9252-A0FA53366D41 Q37374637-4791AF4D-67F9-4E80-91CE-5955B03A405F Q37591876-8C85C76F-959B-4923-88FD-CEF269E2D43D Q38208701-C89977E7-B0FB-4EB4-888C-95DE821999EE Q38225580-8ED40007-0D4D-4C44-9E51-F2F8ED7478A8 Q38243095-4CFBD40F-62A0-4BD0-B72C-9CFA5DC1DCBD Q38763200-F9F1FB79-F3EA-4606-938D-02C16F89C77C Q40410464-90CBC397-2210-4EDB-AE73-2A1084979CC6 Q40415359-0FE03F35-37B1-4D39-B0E7-FC5E00522563 Q41343104-366FF99B-83ED-4D99-BBA9-1770A876F0EA Q41821409-2630A44D-D25A-4E44-8A38-EC5C81853D0F Q43740818-EF18645B-F4FA-421A-BDFD-485B927332C9 Q51107309-6A406B45-3379-43E8-AE80-2F448AA0FE8B Q51415479-E66D96D5-56E4-4EDC-82ED-2A261A0893C1 Q52671840-E2AAAB34-9D32-4820-AF91-917E7EDBFDAB Q52871336-41913CB7-B1DA-46FA-BDCE-39FF9961018D Q53302741-376BA1F0-4442-484E-8E1C-9EDD35D3DCB4 Q53394767-005CC093-1466-4747-A9B7-C979F7143670

P2860

BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.

http://www.wikidata.org/entity/Q38039906

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

BRAF V600E mutation independen ...... with papillary thyroid cancer.

@en

type

label

BRAF V600E mutation independen ...... with papillary thyroid cancer.

@en

prefLabel

BRAF V600E mutation independen ...... with papillary thyroid cancer.

@en

P1433

Q38039906-B033141D-9B38-47FB-9C1D-90A7EDF167C2

P1476

Q38039906-8D3EB3C1-85D5-46B6-881F-C6E21B12E8C4

P2093

Q38039906-14E1D877-45E2-4887-B3E3-15924DCD5471

Q38039906-17E2BC7C-D2AE-4501-B673-E11A5871AC10

Q38039906-268BA659-87BA-4982-9189-8532AB8DC0ED

Q38039906-5B6994AB-9736-4E88-8A6D-2564D131A3ED

Q38039906-80EF3763-511B-468C-B5BA-71FA9C1094B8

Q38039906-A78FB370-B724-4382-A7D9-AFD99D2D2DF1

Q38039906-CBB8E91B-3150-40DE-914B-B7713DB99A92

Q38039906-D3DE81EB-D533-474E-B6DA-6436B2712245

Q38039906-EB777A1F-5548-4962-ABB2-35EF4B5F442D

P2860

Q38039906-02919FF9-5538-4136-A627-C450CD3A2099

Q38039906-12430108-3F29-4C03-B0ED-D7249C02FB40

Q38039906-1358E192-DD50-4F2D-A71F-9A5D6B42FE74

Q38039906-19A91EBA-467E-4595-8E29-214AA28777FA

Q38039906-1B5DB217-20D9-43AE-AE38-3F3C0ACE7C29

Q38039906-1CEA0CDA-CE1F-4EC1-B87D-3C2B9C95625F

Q38039906-2479132F-2E82-4EE9-924F-1329066C1DBF

Q38039906-25960E39-B181-4D4C-B974-0724A76D9DB8

Q38039906-30504830-E208-420C-99D6-FDF5D899F201

Q38039906-56B2AD23-E64B-4CDF-B184-6A1B44E97421

P2888

Q38039906-5EF5C74A-04B7-4B4E-9048-B312E8DE7CE1

P304

Q38039906-23B812AF-BD27-44FE-A0A3-C4EF8387146E

P31

Q38039906-11C95FF5-AA40-4C5E-8684-FC8175AFB083

P356

Q38039906-AFC4D297-F3C4-4808-A3BF-564935780443

P433

Q38039906-93D02CAE-480E-4971-94B8-B188C541DB54

P478

Q38039906-8B3BD4DE-CE8D-441B-A1FD-38DDD2F9B9BA

P577

Q38039906-E10996E9-FD6C-4465-B14D-744A15180A6D

P6179

Q38039906-403DCFA0-88C2-4200-A03B-CD1A66616869

P698

Q38039906-4FBEFEFD-0E1E-4DBF-811D-30BF781C9DCF

P921

Q38039906-74F61C7D-DCF3-4AC2-8908-508E508AD86A

P356

S10434-012-2611-0

P1433

Annals of Surgical Oncology

P1476

BRAF V600E mutation independen ...... with papillary thyroid cancer.

@en

P2093

Gina M Howell

http://www.w3.org/2001/XMLSchema#string

Kelly L McCoy

http://www.w3.org/2001/XMLSchema#string

Linwah Yip

http://www.w3.org/2001/XMLSchema#string

Marina N Nikiforova

http://www.w3.org/2001/XMLSchema#string

Michael T Stang

http://www.w3.org/2001/XMLSchema#string

Michaele J Armstrong

http://www.w3.org/2001/XMLSchema#string

Sally E Carty

http://www.w3.org/2001/XMLSchema#string

Steven P Hodak

http://www.w3.org/2001/XMLSchema#string

Yuri E Nikiforov

http://www.w3.org/2001/XMLSchema#string

P2860

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Central lymph node dissection in differentiated thyroid cancer.

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer.

Micrometastases in thyroid cancer. An important finding?

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

P2888

s10434-012-2611-0

P304

47-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-012-2611-0

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003193105

http://www.w3.org/2001/XMLSchema#string

P698

22941165

http://www.w3.org/2001/XMLSchema#string

P921